Home

Innate Pharma S.A. - American Depositary Shares (IPHA)

1.8300
-0.0900 (-4.69%)
NASDAQ · Last Trade: Apr 6th, 10:53 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News:
By Innate Pharma SA · Via Business Wire · April 3, 2025
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 27, 2025
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 26, 2025
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 25, 2025
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News:
By Innate Pharma SA · Via Business Wire · March 20, 2025
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · February 27, 2025
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Regulatory News:
By Innate Pharma SA · Via Business Wire · February 17, 2025
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 27, 2025
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 21, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 16, 2025
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News:
By Innate Pharma SA · Via Business Wire · January 10, 2025
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 20, 2024
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 9, 2024
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 6, 2024
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · December 3, 2024
Innate Pharma Releases Its 2025 Financial Calendar
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 20, 2024
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 19, 2024
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 13, 2024
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 8, 2024
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Regulatory News:
By Innate Pharma SA · Via Business Wire · November 7, 2024
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Regulatory News:
By Innate Pharma SA · Via Business Wire · October 29, 2024
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Regulatory News:
By Innate Pharma SA · Via Business Wire · October 14, 2024
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Regulatory News:
By Innate Pharma SA · Via Business Wire · September 30, 2024
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
Regulatory News:
By Innate Pharma SA · Via Business Wire · September 23, 2024
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Regulatory News:
By Innate Pharma SA · Via Business Wire · September 12, 2024